MedTrace Logo

Glucocorticoid Therapy for COVID-19 Critically Ill Patients With Severe Acute Respiratory Failure

NCT04244591 · Status: COMPLETED · Phase: PHASE2/PHASE3 · Type: INTERVENTIONAL · Enrollment: 80

Last updated 2020-06-16

No results posted yet for this study

Summary

In this multi-center, randomized, control study, the investigators will evaluate the efficacy and safety of glucocorticoid in combination with standard care for COVID-19 patents with Severe acute respiratory failure.

Conditions

  • COVID-19 Infections

Interventions

DRUG

methylprednisolone therapy

Methylprednisolone 40 mg q12h for 5 days

OTHER

Standard care

Standard care

Sponsors & Collaborators

  • Zhongda Hospital

    collaborator OTHER

  • Zhongnan Hospital

    collaborator OTHER

  • Renmin Hospital of Wuhan University

    collaborator OTHER

  • Peking Union Medical College Hospital

    lead OTHER

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
PARALLEL

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2020-01-26
Primary Completion
2020-04-13
Completion
2020-04-13

Countries

  • China

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT04244591 on ClinicalTrials.gov